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ABSTRACT
Objective The presence of the retrovirus xenotropic
murine leukaemia virus-related virus (XMRV) has been
reported in peripheral blood mononuclear cells of
patients with chronic fatigue syndrome. Considering the
potentially great medical and social relevance of such a
discovery, we investigated whether this finding could be
confirmed in an independent European cohort of patients
with chronic fatigue syndrome.
Design Analysis of a well defined cohort of patients and
matched neighbourhood controls by polymerase chain
reaction.
Setting Certified (ISO 15189) laboratory of clinical
virology in a university hospital in the Netherlands.
Population Between December 1991 and April 1992,
peripheral bloodmononuclear cellswere isolated from76
patients and 69 matched neighbourhood controls. In this
study we tested cells from 32 patients and 43 controls
from whom original cryopreserved phials were still
available.
Main outcome measures Detection of XMRV in peripheral
blood mononuclear cells by real time polymerase chain
reaction assay targeting the XMRV integrase gene and/or
a nested polymerase chain reaction assay targeting the
XMRV gag gene.
ResultsWe detected no XMRV sequences in any of the
patients or controls in either of the assays, in which
relevant positive and negative isolation controls and
polymerase chain reaction controls were included.
Spiking experiments showed that we were able to detect
at least 10 copies of XMRV sequences per 105 peripheral
bloodmononuclear cells by real time as well as by nested
polymerase chain reaction, demonstrating high
sensitivity of both assays.
Conclusions This study failed to show the presence of
XMRV in peripheral blood mononuclear cells of patients
with chronic fatigue syndrome from a Dutch cohort. These
data cast doubt on the claim that XMRV is associated with
chronic fatigue syndrome in the majority of patients.
INTRODUCTION
Chronic fatigue syndrome, also named myalgic ence-
phalitis, is characterised by disabling physical and
mental fatigue, lasting for at least six months, without
an apparent physical cause.1-3 The hallmark of the ill-
ness is debilitating fatigue, but symptoms like myalgia,
disrupted sleep, difficulty with concentration, sore
throat, and lymphadenopathy may also be present,
albeit more variably. More than two thirds of patients
are women. Although the cause is unknown and the
illness may cover more than one entity, many have
suggested that infectious agents have a role.4 Indeed,
the onset of chronic fatigue syndrome is oftenpreceded
by an acute flu-like illness or infectious mononucleosis
with seemingly impaired recovery.5 A role of chronic
infection and changed immunity has been postulated.
Most cases of the illness are sporadic, but some clus-
tered cases have been described, particularly suggest-
ing an infectious cause. However, despite extensive
studies, no causative infectious agent has been conclu-
sively identified, neither has an immune defect been
established to explain the symptoms.2 6
In a recent publication in Science, Lombardi et al7
reported the detection of xenotropic murine leukaemia
virus-related virus (XMRV)—a human gamma retro-
virus that was first identified in tumour tissue of patients
with prostate cancer8—in peripheral blood mononuc-
lear cells of patients with chronic fatigue syndrome. In
that study, XMRV was detected by polymerase chain
reaction in 67% of patients (68 of 101 samples) and in
4% of healthy individuals (eight of 213 samples).
Furthermore, antibodies to XMRV were identified in
the blood of patients but not in controls. Lombardi et
al showed that XMRVwas infectious and transmittable
from clinical material of patients to T cell cultures and a
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permissive cell line. The genetic sequence of XMRV in
patientswasnearly identical to that inpatientswithpros-
tate cancer, indicating that the identified retrovirus is a
genuine human virus rather than a mouse leukaemia
virus contamination.
This report was considered a major scientific break-
through and attracted a lot of attention. However, the
paper fell short in the description of the patients: what
was the nature of the cohort, what was the age and sex
distribution, how well were the controls matched?
Investigation of an independent cohort is therefore
necessary before a causal association between
XMRV infection and the development of chronic fati-
gue syndrome can be ascertained. We investigated the
presence of XMRV in a well established Dutch cohort
of patients with chronic fatigue syndrome using pre-
viously described real time and nested polymerase
chain reaction assays on two different target genes.7-9
METHODS
Patient cohort
All patients and controls examined in this study were
part of a Dutch cohort of 298 patients, which has been
described in detail.10 11 All patients of this cohort ful-
filled the Oxford criteria and reported severe, unex-
plained, debilitating fatigue of at least one year in
duration.12 The median duration of their symptoms
was seven years (range 2-45 years). The enrolled
patients came to our outpatient clinic twice in a three
month period. On the second visit, each patient was
accompanied by a neighbourhood control (who was
selected by the patient) of the same sex and within
two years of the same age. Patients and controls visited
our clinic betweenDecember 1991 andApril 1992.All
patients underwent a physical examination and an
extensive laboratory work-up and completed a set of
questionnaires.10 Blood samples were obtained from
76 patients (randomly chosen using a table of random
numbers10 from the 298 patients described above) and
69 matched neighbourhood controls. Blood samples
were sent to the central laboratory of the blood transfu-
sion service in Amsterdam, where peripheral blood
mononuclear cells were isolated for a study of lympho-
cyte subsets and apoptosis.11 After isolation, a fraction
of the peripheral bloodmononuclear cells was directly
cryopreserved according to a standard protocol in a
computerised device. Cells were aliquoted in phials
and stored with 10% dimethyl sulfoxide at −196ºC
(liquid nitrogen) in a density of about 107 cells per ml.
The quality of the storage conditions at the central
laboratory of the blood transfusion service has been
amply demonstrated by Jansen et al, who showed
that peripheral blood mononuclear cells stored for
12 years remained fully viable and immunologically
competent.13
In this study, we examined peripheral blood mono-
nuclear cells of all patients (n=32) and controls (n=43)
from whom original cryopreserved vials were still
available. This group included 25 patients and their
matched controls, as well as seven patients and 18 con-
trols that were not matched to each other. The male to
female ratio of the patient group that was tested in this
studywas 1:2. Average age of themale patients was 40.
7 years (range 25-61) and of female patients was 40.
5 years (25-67).
Nucleic acid isolation and copy DNA synthesis
Nucleic acid was isolated from 100 µl of peripheral
blood mononuclear cells (about 0.5 to 2×106 cells)
using the MagNA-Pure LC and the MagNA-Pure LC
Total Nucleic Acid Isolation Kit (Roche Diagnostics,
Almere, Netherlands) according to the instructions of
the manufacturer and eluted in 50 µl of elution buffer.
A fixed amount of phocine distemper virus, a para-
myxovirus that was used as internal control, was
added to the samples before nucleic acid isolation so
that we could monitor RNA quality and possible inhi-
bition of amplification of the samples.14 RNA in the
total nucleic acid isolates was reverse transcribed to
copy DNA using the TaqMan Reverse Transcription
Reagents kit (Applied Biosystems, Nieuwerkerk aan
den IJssel, Netherlands) in a 50 µl reaction mix con-
taining 20 µl of nucleic acid isolate (concentration 25-
150 ng per µl) and random hexamers as primers,
according to the manufacturer’s instructions.
Real time polymerase chain reaction assay
A duplex real time polymerase chain reaction assay
was developed, adapted from the XMRV integrase
real time polymerase chain reaction assay described
by Schlaberg et al,9 to detect XMRV and phocine dis-
temper virus simultaneously. The reaction mixture
contained 12.5 µl of 2X LightCycler 480 Probes Mas-
ter (Roche Diagnostics), 1 µM of each primer and
400 nM of each probe, and 5 µl of copy DNA in a
reaction volume of 25 µl. The XMRV and phocine
distemper virus primers were as described.9 14 The
XMRV probe was used as a 5´-(6-carboxyfluores-
cein)-labelled, locked nucleic acid hydrolysis probe
and the phocine distemper virus probe was used as a
5´-yakima yellow-labelled, locked nucleic acid hydro-
lysis probe. All primers and probes used in this study
are shown in the table. Cycling conditions were 95°C
for five minutes, followed by 50 cycles of 95°C for
15 seconds and 60°C for 45 seconds using the Light-
Cycler 480 instrument (RocheDiagnostics). The result
of the sample was considered a valid result only if the
crossing point value for the spiked phocine distemper
virus was within two cycles of the average of uninhib-
ited samples.
Positive and negative controls for isolation, reverse
transcription, and polymerase chain reaction were
included in each run. β-globin real time polymerase
chain reactionwas performedusing primers andhybri-
disation probes as described.15 Mean crossing point
value of β-globin real time polymerase chain reaction
assay was 23.84, standard deviation 0.95. As a positive
control for the polymerase chain reaction assay, we
used nucleic acid isolated from 22Rv1, a prostate car-
cinoma cell line (American Type Culture Collection
numberCRL-2505) that was recently shown to contain
multiple integrated copies of XMRV and to produce
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high levels of infectious virus.16 Total nucleic acid iso-
lation and sample preparation from this cell line was as
described above for peripheral blood mononuclear
cells.
To determine the sensitivity of the XMRV real time
polymerase chain reaction assay, we generated a 192
base pairs XMRV integrase polymerase chain reaction
product using primers XMRV-F2 (which is located
upstream of XMRV-F1) and XMRV-R3 (which is
located downstream of XMRV-R2), and 22Rv1 copy
DNA as a template. The polymerase chain reaction
product was purified using the Wizard PCR preps
DNA purification system (Promega Benelux, Leiden,
Netherlands). The concentration was determined
using a NanoDrop 1000 (Thermo Scientific/Isogen,
De Meern, Netherlands) and the number of copies
per µl was calculated. A dilution series was made in
which 101 to 107 copies of the calibrator were added
to 106 peripheral blood mononuclear cells before
nucleic acid isolation. This corresponds to 1 to 106
copies per reaction, since a tenth of the isolated nucleic
acid was used as input for the polymerase chain reac-
tion, which was performed as described above.
Nested polymerase chain reaction assay
The XMRV gag nested polymerase chain reaction
assay was adapted from Urisman et al.8 The reaction
mixtures contained 25 µl of 2X PCR Master (Roche
Diagnostics), and 200 nM of each primer in a reaction
volume of 50 µl. In the first reaction, 5 µl of copyDNA
was used. Subsequently, 5 µl of the first reaction was
used as input for the nested reaction. Primers were as
described, except for the reverse primer of the nested
reaction (GAG-I-R),whichwas replaced byGAG-I-R2
to yield a 92 base pairs reaction product (we used pri-
mer GAG-I-R2 because it produced less background
in the nested reverse transcription polymerase chain
reaction). The target sequence of GAG-I-R2 is 100%
conserved among all XMRV isolates published to
date (data not shown). Cycling conditions were as pre-
viously described.8 Polymerase chain reaction pro-
ducts (20 µl) were analysed on a 2.5% agarose gel.
To determine the sensitivity of our XMRV nested
polymerase chain reaction assay, a 708 base pairs
XMRV gag polymerase chain reaction product was
Sequences of primers and probes used in this study
Sequence Reference
XMRV integrase gene
XMRV-F1 5′-CGAGAGGCAGCCATGAAGG-3′ 9
XMRV-F2 5′-AACCTGATGGCAGATCAAGC-3′ This study
XMRV-R1 5′-GAGATCTGTTTCGGTGTAATGGAAA-3′ 9
XMRV-R2 5′-CCCAGTTCCCGTAGTCTTTTGAG-3′ 9
XMRV-R3 5′-TTTGCCTTGTAGGACCCAAT-3′ This study
XMRV-Probe 5′-AGTTCTAGAAACCTCTACACTC- 3′ 9
XMRV gag gene
GAG-O-F 5′-CGCGTCTGATTTGTTTTGTT-3′ 8
GAG-O-R 5′-CCGCCTCTTCTTCATTGTTC-3′ 8
GAG-I-F 5′-TCTCGAGATCATGGGACAGA-3′ 8
GAG-I-R 5′-AGAGGGTAAGGGCAGGGTAA-3′ 8
GAG-I-R2 5′-CAGACTGGTTGGATGCAATG-3′ This study
GAG-UNIQ-F 5′-GACTTTTTGGAGTGGCTTTGT-3′ 17
PDV haemagglutinin gene
PDV-F 5′-GGTGGGTGCCTTTTACAAGAAC-3′ 14
PDV-R 5′-ATCTTCTTTCCTCAACCTCGTCC-3′ 14
PDV-probe 5′-ATGCAAGGGCCAATT-3′ 14
Human β-globin gene
bGLO-for 5′-GAGCCATCTATTGCTTACATTTGC-3′ 15
bGLO-rev 5′-TTGGTCTCCTTAAACCTGTCTTGT-3′ 15
bGLO-FL 5′-CCAGGGCCTCACCACCAACTTC-3′ 15
bGLO-LC640 5′-CCACGTTCACCTTGCCCCACAG-3′ 15
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Fig 1 | Results of XMRV integrase real time polymerase chain
reaction assay. (A) All 32 patients with chronic fatigue
syndrome (CFS) compared with positive 22Rv1 control, which
yielded a crossing point value of about 23. Results for
neighbourhood controls not shown. (B) 22Rv1 total nucleic
acid (DNA, solid), reverse transcribed total nucleic acid (cDNA,
dashed). The additional reverse transcription step increased
the sensitivity of the polymerase chain reaction, decreasing
the crossing point (Cp) value by 3.5. One of three independent
experiments is shown. (C) Sensitivity of the assay. The inlay
shows linear relation between number of spiked molecules
and crossing point value from 101 to 106 copies per reaction
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 6
generated using primers GAG-UNIQ-F described by
Dong et al17 (which is located upstream of GAG-O-F)
and GAG-O-R, and 22Rv1 copy DNA as a template.
Purification and determination of the amount of the
polymerase chain reaction product were performed
as described above for the real time polymerase chain
reaction calibrator. A dilution series was made and 101
to 107 copies of the calibrator were added to 106 per-
ipheral blood mononuclear cells prior to nucleic acid
isolation. This corresponds to 1 to 106 per reaction
since a tenth of the isolated nucleic acid was used as
input for the nested polymerase chain reaction, which
was performed as described above. In the same way,
we tested the sensitivity of the nested polymerase chain
reaction assay described by Urisman et al8 using pri-
mer GAG-I-R instead of GAG-I-R2.
RESULTS
Total nucleic acid was isolated from peripheral blood
mononuclear cells of 32 patients and 43 healthy con-
trols. Nucleic acid was subjected to copy DNA synth-
esis to increase the sensitivity of our polymerase chain
reaction assays. This was done because we observed
that the real time polymerase chain reaction assay on
nucleic acid isolated from a XMRV positive prostate
cancer cell line, 22Rv1, and subjected to copy DNA
synthesis—allowing detection of both proviral DNA
and viral RNA—was about 10 times more sensitive
than without copy DNA synthesis (fig 1B). Neverthe-
less, all samples from patients with chronic fatigue syn-
drome and from controls tested negative for both the
XMRV integrase gene (fig 1) and the XMRV gag gene
(fig 2).
Our negative XMRV polymerase chain reaction
results were unlikely to be due to low amounts of
nucleic acid tested or low sensitivity of the assays
used.We used 50-300 ng of total nucleic acid fromper-
ipheral bloodmononuclear cells per polymerase chain
reaction, which is similar to the amount used by Lom-
bardi et al.7 Moreover, by adding 10-fold serial dilu-
tions of a defined amount of template DNA to
peripheral blood mononuclear cells before nucleic
acid isolation, we demonstrated that both the real
time polymerase chain reaction assay (fig 1C) and the
nested polymerase chain reaction assay (fig 2B) could
detect at least 10 copies of XMRV per 105 peripheral
blood mononuclear cells, indicating a high sensitivity.
A similar sensitivity of the nested polymerase chain
reaction assay was observed when we used the same
primers as described by Urisman et al (inner reverse
primer GAG-I-R instead of the inner reverse primer
GAG-I-R2 used in our assay) (data not shown).8
Our negative XMRV polymerase chain reaction
results are also unlikely to be due to problems with
nucleic acid isolation, loss of RNA or DNA integrity,
synthesis of copy DNA, or the polymerase chain reac-
tion procedure, since both the phocine distemper virus
RNA (an internal control of which a fixed amount was
added to each of the samples before nucleic acid isola-
tion) and the β-globin genewere efficiently amplified in
all samples tested (data not shown).
Fig 2 | Results of XMRV gag nested polymerase chain reaction
assay. (A) Results for 11 patients with chronic fatigue
syndrome and negative controls. Results for neighbourhood
controls not shown. (1) The positive 22Rv1 control yielded a
product of the expected size of 92 base pairs (arrow); (2)
negative polymerase chain reaction control; (3) phocine
distemper virus (internal control); (4) negative reverse
transcription control; (5)-(11) and (13)-(16) patient samples;
(12) negative isolation control; (M) 100 base pairs size
marker. (B) Sensitivity of the XMRV gag first polymerase chain
reaction. (C) Sensitivity of the nested reaction. White arrows
indicate the 613 base pairs (B) and 92 base pairs (C) reaction
products. (1) 22Rv1; (2) negative polymerase chain reaction
control; (3-9), dilution series of 106 to 100 copies of calibrator
per reaction; (10) negative isolation control; (11) negative
nested polymerase chain reaction control; (12) positive
nested polymerase chain reaction control (22Rv1); (M) 100
base pairs size marker. Black arrows 1-4 in (C) indicate
polymerase chain reaction products that are formed in the
nested reaction (see D). (D) Positions of the gag primers and
the gag polymerase chain reaction products formed in the
nested reaction. In addition to the primers of the nested
reaction (GAG-I-F, I-F and GAG-I-R2, I-R2), primers from the
first reaction (GAG-O-F, O-F and GAG-O-R, O-R) are also
present in the nested reaction, yielding reaction products 1-4
that correspond to the black arrows in (C). Numbers represent
the positions on the XMRV genome (VP42, accession
DQ241302)
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DISCUSSION
Principal findings
We assessed the presence of XMRV in peripheral
blood mononuclear cells isolated from patients with
chronic fatigue syndrome from a well characterised
Dutch cohort. We found no evidence for the presence
of XMRV in any of these sporadic cases of chronic
fatigue syndrome or in controls.
Strengths and limitations of the study
A limitation of our study is that the numbers of patients
and controls in our study were relatively small. Based
on these low numbers, the upper limit of the 95% con-
fidence interval is a prevalence of 9% for the patient
group and 7% for the control group, as calculated
according to Eypasch et al (by the formula p=3/n).18
Although we cannot formally rule out a role of
XMRV, our data cast doubt on the claim that this
virus is associated with chronic fatigue syndrome in
the majority of patients.
Comparison with findings of previous studies
The results of the present study are in contrast with the
findings of Lombardi et al, who detected XMRV in
67% of the patients with chronic fatigue syndrome
analysed.7 Technical aspects are unlikely to explain
the difference in XMRV positivity rate between our
data and their data. The possibility that the relative
long duration of chronic fatigue syndrome in our
cohortmay have led to our negative results seems unli-
kely, because retroviruses integrate into the genome of
the host. Given the high sensitivity of our real time and
nested polymerase chain reaction assays, a positive sig-
nal should have been obtained in the presence of the
virus. The fact that our sampleswere cryopreserved for
many years is also unlikely to account for the negative
results. Peripheral blood mononuclear cells cryo-
preserved for 12 years under these conditions have
remained viable and immunocompetent.13 Moreover,
we found no difference in efficiency of β-globin gene
amplication from stored samples compared with sam-
ples that were used directly after isolation (data not
shown), indicating good quantity and quality of the
nucleic acid isolated from cryopreserved samples.
As technical aspects do not seem to provide an
explanation, the difference might be explained by the
two cohorts studied. Our patients met the Oxford cri-
teria for chronic fatigue syndrome, whereas the
patients studied by Lombardi et al were reported to
fulfil the Centers for Disease Control criteria,7 but
this is unlikely to explain the absence of XMRV in
our patients’ samples. Unfortunately, the paper of
Lombardi and colleagues lacked a clear description
of their patient cohort. Recently, at the Tri-Society
Annual Conference 2009 in Lisbon, a presentation
reported that the peripheral blood mononuclear cells
were derived from patients from the outbreak of
chronic fatigue syndrome at Incline village at the
northern border of Lake Tahoe, United States (1984-
5).19 This outbreak has long been thought to have been
caused by a viral infection andhas been associatedwith
a number of viruses, most notably Epstein-Barr virus20
and human herpes virus 6,21 but firm evidence for a
role of viruses in this particular outbreak has never
beenprovided. It is possible that the studyof Lombardi
et al has unravelled the viral cause of the chronic fati-
gue syndromeoutbreak, but it seems unlikely that their
study demonstrates a viral association for sporadic
chronic fatigue syndrome cases, such as those we
tested, or represents the majority of patients. Studies
of XMRV in sporadic chronic fatigue syndrome cases
from the United States would be of great interest.
XMRV was initially identified in tumour tissue of
about 10% of patients with prostate cancer in the Uni-
ted States.8 This association was recently confirmed in
another independent study from the United States, in
which XMRV was detected in 23% of patients.9
Remarkably, in three independent European cohorts
of patients with prostate cancer, no XMRV was
detected.22-24 Whether this discrepancy is due to differ-
ences in the geographic distribution of the virus
remains to be established.
Recently, a team from theUnitedKingdomreported
the failure to detect XMRV in all 186 tested peripheral
blood mononuclear cell samples from a well charac-
terised cohort of British patients with chronic fatigue
syndrome.25 This team, however, did not use the
same primer sets as used by Lombardi et al, leaving
open a possible explanation for the difference in
results. In our study, we used the same primer sets as
used by Lombardi et al. Although our patient group
was relatively small and more research is required,
our findings—together with those of Erlwein et al25—
cast doubt on the claim that XMRV is associated with
chronic fatigue syndrome in the majority of patients.
Lombardi et al also detected XMRV in about 4% of
healthy controls.7 We failed to detect XMRV in per-
ipheral blood mononuclear cells of healthy controls in
our study, but the number of controls tested (n=43) is
too low to exclude the occurrence of XMRV in blood
in a part of the population. Clearly, more research is
needed to establish the distribution of XMRV in
healthy controls and, of course, in blood supply pro-
ducts in Europe and in the United States.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Chronic fatigue syndrome is a debilitating disease of unknown cause that affects millions of
people worldwide
A study from the United States reported the detection of the retrovirus xenotropic murine
leukaemia virus-related virus (XMRV) in peripheral blood mononuclear cells in a cohort of
patients with chronic fatigue syndrome, suggesting a possible causal relation and a
satisfactory explanation for their problems
WHAT THIS PAPER ADDS
We found no evidence for the occurrence of XMRV in peripheral blood mononuclear cells of
patients with chronic fatigue syndrome from a well defined Dutch cohort
These data cast doubt on the claim that XMRV is associated with chronic fatigue syndrome in
the majority of patients
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Implications
In conclusion, we found no evidence for a role of
XMRV in the cause of chronic fatigue syndrome in
Dutch patients. Over the past decades we have seen a
series of papers prematurely claiming the discovery of
the microbial cause of chronic fatigue syndrome.
Regrettably, thus far none of these claims has been sub-
stantiated.
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